Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, FIH, Randomized, Double-blind, Single-dose, Parallel-group, 3-arm Study Comparing the PK, Safety, Tolerability, and Immunogenicity Profiles of AVT04, EU-approved Stelara®, and US-licensed Stelara® in Healthy Adult Subjects

NCT04744363 is registered in ClinicalTrials.gov with Alvotech Swiss AG as lead sponsor.

NCT NCT04744363
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04744363 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, FIH, Randomized, Double-blind, Single-dose, Parallel-group, 3-arm Study Comparing the PK, Safety, Tolerability, and Immunogenicity Profiles of AVT04, EU-approved Stelara®, and US-licensed Stelara® in Healthy Adult Subjects
Lead sponsor
Alvotech Swiss AG
Phase
Phase 1
Overall status
Completed
Start date
May 25, 2021
Completion date
March 19, 2022
Enrollment
294 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis